Ubrogepant: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Ubrogepant. Educational only — not medical advice.

Labeled uses

UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine.

Source: FDA labeling via NIH DailyMed (set fd9f9458…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.